116169-07-4

Usage

Uses

Used in Food Industry:
Methyl 3-ethoxy-5-hydroxybenzoate is used as a flavoring agent for its sweet, vanilla-like aroma, enhancing the taste and smell of various food products.
Used in Cosmetic Industry:
This organic compound is used as a fragrance ingredient in perfumes and other cosmetic products, providing a pleasant scent and improving the sensory experience for users.
Used as a Preservative:
Methyl 3-ethoxy-5-hydroxybenzoate is utilized for its antioxidant properties, acting as a preservative to extend the shelf life of various products by preventing oxidation and spoilage.

Upstream product

• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 75-03-6 ethyl iodide 
• 74-96-4 ethyl bromide 

Downstream Products

• 198623-55-1 3,5-diethoxybenzoic acid methyl ester 
• 909854-02-0 3-ethoxy-5-(tetrahydro-pyran-4-yloxy)-benzoic acid methyl ester 
• 909854-00-8 3-ethoxy-5-(2,2,2-trifluoro-ethoxy)-benzoic acid methyl ester 
• 1147012-22-3 methyl 3-ethoxy-5-[2-(methylsulfonyl)phenoxy]-benzoate 
• 1041204-76-5 methyl 3-ethoxy-5-trifluoromethanesulfonyloxybenzoate 

Relevant academic research and scientific papers

IMIDAZOPYRIDINE COMPOUNDS

Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of formula (I) wherein the variables are as defined herein.

Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators

Identification and synthesis of novel 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as glucokinase activators are described. Removal of an aniline structure of the prototype lead (2a) and incorporation of an alkoxy or phenoxy substituent led to the identifica

Aspartyl protease inhibitors

The present invention provides compounds having the formula: wherein R1, R′, R2, R3, R3′, R4, X1, X2 and X3 are as defined herein, and pharmaceutical compositions thereof. The present invention also provides methods of inhibiting proteases, more specifically aspartyl proteases. In certain embodiments, compounds inhibit BACE (β-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by β-amyloid deposits in the brain (including, but not limited to, Alzheimer's Disease). The present invention also provides methods for preparing compounds of the invention.

ASPARTYL PROTEASE INHIBITORS

The present invention provides compounds having formula (I): wherein R’, R0, R1, X1, R2, R3, R3’, X2, X3, and R4 are as defined herein, and pharmaceuticals compositions thereof. The present invention also provides methods of inhibiting proteases, more specially aspartyl proteases. In certain embodiments, compounds inhibit BACE (β-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by β-amyloid deposits in the brain (including, but not limited to, Alzheimer’s Disease). The present invention also provides methods for preparing compounds of the invention.